Oncology Injection Drug Sales

Oncology Injection Drug Sales Market Outlook

The global oncology injection drug sales market is projected to reach approximately USD 96 billion by 2035, growing at a compound annual growth rate (CAGR) of around 7.5%. This market growth is significantly driven by the increasing prevalence of various forms of cancer globally, leading to greater demand for innovative and effective treatment options. In addition, advancements in biotechnology and pharmaceutical research are yielding novel drugs that target specific cancer types with improved efficacy and reduced side effects, appealing to both healthcare providers and patients alike. The rising investment in healthcare infrastructure and increasing government funding for cancer research further bolster this market. Additionally, the growing awareness and accessibility of advanced cancer therapies are contributing to the market expansion.

Growth Factor of the Market

One of the primary growth factors for the oncology injection drug sales market is the escalating incidence of cancer worldwide. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, which has prompted a surge in demand for effective therapeutic interventions. Furthermore, the continuous evolution of cancer treatment modalities, including precision medicine and personalized therapies, is also playing a significant role in enhancing treatment outcomes. The integration of advanced technologies like artificial intelligence and machine learning in drug development processes is leading to faster and more efficient drug discovery, further driving market growth. Additionally, the rising geriatric population, who are more susceptible to cancer, alongside changing lifestyles and environmental factors, is increasing the need for innovative oncology drugs. Lastly, partnerships and collaborations among pharmaceutical companies for drug development and commercialization are significantly amplifying the market's growth trajectory.

Key Highlights of the Market

• The global oncology injection drug sales market is expected to grow at a CAGR of 7.5% from 2025 to 2035.
• Monoclonal antibodies are forecasted to dominate the product type segment, accounting for a major share of the market.
• North America is anticipated to hold the largest market share, driven by technological advancements and high healthcare expenditure.
• Solid tumors are expected to be the leading application segment, reflecting the high incidence rate of this cancer type.
• The trend toward personalized medicine is shaping the future of oncology drug development, leading to more effective therapies.

By Product Type

Monoclonal Antibodies:

Monoclonal antibodies have emerged as a pivotal component of the oncology injection drug sales market, primarily due to their targeted action against cancer cells. These biologics work by binding to specific antigens present on the surface of cancer cells, marking them for destruction by the immune system. The effectiveness of monoclonal antibodies in treating various cancer types, including breast, colorectal, and lymphomas, has led to a significant increase in their adoption. Moreover, ongoing research and clinical trials are focused on developing new monoclonal antibodies with enhanced efficacy and safety profiles, further propelling this segment's growth. Key products in this category, such as Trastuzumab and Rituximab, have already demonstrated substantial market success, indicating a robust future for monoclonal antibodies in oncology therapies.

Chemotherapy Drugs:

Chemotherapy drugs remain a cornerstone in the treatment of cancer, particularly for aggressive malignancies that require rapid intervention. These agents work by targeting rapidly dividing cells, which is a characteristic of cancer cells. Despite the emergence of newer, targeted therapies, chemotherapy continues to be widely used due to its effectiveness and established track record. This segment encompasses a variety of drug classes, including alkylating agents, antimetabolites, and plant alkaloids. The increasing number of clinical applications for chemotherapy drugs, coupled with ongoing research to reduce side effects and improve outcomes, is expected to sustain the demand for these products in the oncology landscape. Furthermore, combination therapies that use chemotherapy alongside targeted therapies are gaining traction, enhancing the effectiveness of cancer treatment protocols.

Targeted Therapy Drugs:

Targeted therapy drugs represent a more recent advancement in cancer treatment, focusing on specific molecular targets associated with cancer progression. Unlike traditional chemotherapy, these drugs aim to interfere with the specific signaling pathways that enable cancer cells to grow and proliferate. The introduction of targeted therapies has revolutionized the treatment of various cancers, particularly those with identifiable genetic mutations, such as EGFR mutations in lung cancer. This market segment is rapidly growing, supported by increasing approvals of targeted agents and a shift towards personalized cancer treatment. The success of targeted therapies in improving survival rates and minimizing adverse effects compared to conventional treatments is further driving this segment, making it a key area of focus for pharmaceutical research and development.

Immunotherapy Drugs:

Immunotherapy drugs have transformed the oncology field by leveraging the body’s immune system to fight cancer. This category includes therapies like checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies that stimulate an immune response against cancer cells. The growing understanding of the immune system's role in cancer treatment has led to significant advancements in immunotherapy, resulting in remarkable outcomes for patients with previously untreatable cancers. The popularity of immunotherapy is reflected in its rapid market growth and the approval of various products such as Pembrolizumab and Ipilimumab. The continuous research into new immunotherapeutic agents and combination therapies is expected to further enhance the effectiveness of cancer treatments and expand the market for immunotherapy drugs.

Hormone Therapy Drugs:

Hormone therapy drugs are particularly effective in treating cancers that are hormone-sensitive, such as breast and prostate cancer. These drugs work by blocking the body’s natural hormones or altering hormone levels to slow or stop cancer growth. The effectiveness of hormone therapy in managing cancer progression and improving patient quality of life has led to its sustained use in oncology treatment regimens. The ongoing development of new hormone therapy agents, alongside research into their use in combination with other treatments, is expected to sustain growth in this segment. The increasing number of clinical trials focusing on hormone receptor-positive cancers highlights the significance of this category within the oncology injection drug sales market.

By Application

Solid Tumors:

Solid tumors represent the largest application segment within the oncology injection drug sales market, encompassing a wide range of cancers that form solid masses of tissue. This category includes various malignancies such as breast, lung, colorectal, and prostate cancers, which are among the most diagnosed cancers globally. The substantial prevalence of solid tumors has resulted in a high demand for effective treatment options, including chemotherapy, targeted therapies, and immunotherapies. Continuous advancements in diagnostic techniques and treatment modalities are driving market growth within this segment. Moreover, the increasing focus on personalized medicine, which tailors treatment plans to individual tumor characteristics, is further transforming the landscape of solid tumor management.

Hematologic Malignancies:

Hematologic malignancies, which include cancers of the blood such as leukemia, lymphoma, and myeloma, constitute a significant segment of the oncology injection drug sales market. The treatment of these conditions often involves a combination of chemotherapy, immunotherapy, and targeted therapies, reflecting the complexity of managing blood cancers. The increasing incidence of hematologic malignancies is driving demand for specialized treatments, leading to a surge in research and development within this area. Innovative therapies, such as CAR T-cell therapy, have shown promising results in treating refractory cases, further enhancing market growth. The ongoing efforts to discover new therapeutic agents and improve existing treatments are expected to continue shaping this segment's trajectory in the coming years.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for oncology injection drugs, providing a wide range of cancer treatment services. The hospital setting is crucial for administering complex therapies that require close monitoring and specialized care, including chemotherapy and immunotherapy regimes. With the rising number of cancer patients requiring treatment, hospitals are increasingly investing in oncology departments and services to meet demand. Furthermore, the availability of oncology specialists and advanced treatment options in hospitals enhances patient outcomes, driving the growth of this distribution channel. As healthcare systems continue to evolve and expand, the role of hospitals in the oncology drug market remains significant, contributing substantially to overall sales figures.

Specialty Clinics:

Specialty clinics have gained prominence as a crucial distribution channel in the oncology injection drug sales market, focusing specifically on cancer treatment and management. These clinics offer a tailored approach to patient care, providing specialized services and therapies that cater to individual cancer types and treatment protocols. The increasing trend toward outpatient treatments for certain cancer therapies is driving the growth of specialty clinics, as patients seek more convenient and accessible care options. Specialty clinics often collaborate with pharmaceutical companies for access to the latest therapies and clinical trials, enhancing their service offerings. This focus on specialized care not only improves patient satisfaction but also helps in optimizing treatment outcomes, thereby solidifying the role of specialty clinics within the oncology landscape.

Retail Pharmacies:

Retail pharmacies play an essential role in the distribution of oncology injection drugs, particularly for oral and self-administered therapies. As the treatment landscape for cancer continues to evolve, the convenience of obtaining medications from retail pharmacies is becoming increasingly attractive to patients. This channel enables patients to access their prescriptions more easily, facilitating adherence to treatment plans. Additionally, many retail pharmacies have begun offering specialized services, including consultations and support programs for oncology patients, enhancing their role in cancer care. The integration of retail pharmacies into the broader healthcare ecosystem is expected to continue, making them a critical distribution channel in the oncology injection drug market.

By Ingredient Type

Pembrolizumab:

Pembrolizumab, a leading immunotherapy drug, has significantly impacted the oncology injection drug sales market by offering a checkpoint inhibitor option for various cancers, including melanoma, lung cancer, and head and neck cancers. It works by inhibiting the PD-1 pathway, thus enhancing the immune response against tumors. The clinical success of Pembrolizumab is marked by its approval across multiple indications, driving its widespread use and adoption. The ongoing research into its efficacy in combination with other treatment modalities is expected to propel its market share further. As the understanding of immune checkpoint inhibitors continues to grow, Pembrolizumab remains at the forefront of innovative cancer therapies.

Rituximab:

Rituximab is another pivotal drug within the oncology injection market, primarily used for treating hematologic malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a monoclonal antibody, Rituximab targets the CD20 antigen on B-cells, leading to cell death and improved outcomes for patients. The long-standing effectiveness of Rituximab has established it as a cornerstone in hematology-oncology, and its continued use in combination therapies underscores its significance. The product's market presence is expected to remain strong due to ongoing clinical research, which aims to optimize its application in various treatment settings.

Trastuzumab:

Trastuzumab is a targeted therapy that has revolutionized the treatment of HER2-positive breast cancer. This monoclonal antibody works by binding to the HER2 receptor, inhibiting tumor growth and enhancing the effectiveness of chemotherapy. Trastuzumab's success is evident in its widespread adoption and the development of biosimilars that offer more affordable options for patients. The ongoing research into Trastuzumab's combinations with other therapeutic agents for improved efficacy in various cancer types exemplifies its critical role in oncology. Furthermore, its established safety profile contributes to its attractiveness for patients and healthcare providers alike, driving continued sales in the oncology injection drug market.

Bevacizumab:

Bevacizumab, a monoclonal antibody that inhibits angiogenesis, plays a crucial role in the treatment of several solid tumors, including colorectal, lung, and renal cancers. By targeting vascular endothelial growth factor (VEGF), Bevacizumab disrupts the blood supply to tumors, effectively slowing their growth. The drug's application in combination therapies has enhanced its market presence, demonstrating improved survival rates for patients with advanced-stage cancers. Continued clinical research and trials exploring Bevacizumab's effectiveness in new indications and combinations are expected to further solidify its position in the oncology drug market. The increasing adoption of personalized medicine approaches also supports Bevacizumab's relevance in contemporary cancer treatment strategies.

Ipilimumab:

Ipilimumab is a significant immunotherapy drug that aids in treating melanoma by enhancing immune response through CTLA-4 inhibition. Its unique mechanism of action distinguishes it in the oncology drug landscape, making it an essential option for patients with advanced melanoma. The effectiveness of Ipilimumab, especially when used in combination with other immune checkpoint inhibitors, has led to substantial improvements in patient outcomes. Ongoing research and clinical trials continue to explore its potential in various cancer types, expanding its role within the oncology injection drug market. As the demand for innovative and effective cancer therapies continues to rise, Ipilimumab's significant contribution to treatment regimens will likely remain vital in the coming years.

By Region

In North America, the oncology injection drug sales market is the largest, driven by a well-established healthcare infrastructure, high levels of healthcare spending, and a robust pipeline of innovative therapies. The United States accounts for a significant share of the North American market due to the high prevalence of cancer and a strong focus on research and development in oncology. The market is projected to grow at a CAGR of 8% from 2025 to 2035, supported by increasing government investments in healthcare and cancer research initiatives. The presence of major pharmaceutical companies and advanced treatment options also contribute to the dominance of North America in the global oncology drug market.

Europe holds a substantial share of the oncology injection drug sales market, driven by increasing cancer incidence rates and a growing emphasis on personalized medicine. Countries such as Germany, the UK, and France are at the forefront of oncology drug development and distribution within the region. The European market is witnessing a shift towards innovative treatment solutions, including targeted therapies and immunotherapies, aligning with global healthcare trends. As regulatory bodies continue to streamline drug approval processes, the European market is expected to maintain steady growth, enhancing its contribution to the global oncology injection drug landscape.

Opportunities

The oncology injection drug sales market presents numerous opportunities, particularly in the realm of personalized medicine. As understanding of genetic and molecular profiles of various cancers evolves, the development of personalized therapies tailored to individual patients is becoming increasingly prevalent. This paradigm shift not only enhances treatment efficacy but also reduces adverse effects, making cancer treatment more tolerable for patients. Pharmaceutical companies that invest in research and development to create targeted therapies are likely to capitalize on this growing trend, thereby positioning themselves as leaders in the oncology market. Additionally, expanding access to oncology care through digital health technologies, telemedicine, and mobile health applications presents an opportunity for stakeholders to improve patient engagement and adherence to treatment protocols.

Another significant opportunity lies in the rising demand for combination therapies, which involve using multiple treatment modalities to enhance patient outcomes. The integration of targeted therapies, immunotherapies, and traditional chemotherapy is gaining traction, as studies continue to demonstrate the efficacy of such approaches. Pharmaceutical companies that can effectively develop and market combination therapies will likely see increased sales and market share. Moreover, the growing number of collaborations and partnerships between academic institutions and pharmaceutical companies for drug development is expected to accelerate innovation in the oncology space. These collaborative efforts may lead to breakthrough therapies that address unmet clinical needs, further propelling the growth of the oncology injection drug sales market.

Threats

The oncology injection drug sales market faces several threats, including the increasing prevalence of generic competition and biosimilars that undermine the pricing power of established branded products. As patents expire for several key oncology drugs, the entry of generic versions into the market can lead to significant pricing pressure, potentially impacting revenue for pharmaceutical companies. Additionally, the presence of biosimilars can provide patients with more affordable options, further challenging the market share of original biologics. Furthermore, stringent regulatory environments and the complexity of obtaining approval for new oncology drugs can also pose risks for companies, as lengthy approval processes may delay market entry and affect profitability. The financial burden associated with cancer treatment can also lead to decreased patient adherence and, consequently, reduced drug sales.

Another significant restraining factor in the oncology injection drug sales market is the rising cost of drug development and the complexity of bringing new therapies to market. The lengthy and expensive process of clinical trials, coupled with the high failure rate of oncology drugs in development, creates an uncertain landscape for pharmaceutical companies. This financial strain can deter smaller companies from investing in oncology research, limiting innovation and competition. Additionally, economic constraints and healthcare funding issues in various regions can impact patient access to new therapies, further restraining market growth. The challenge of balancing cost-effectiveness with the need for innovative treatments remains a critical concern for stakeholders in the oncology drug market.

Competitor Outlook

• Roche Holding AG
• Merck & Co., Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Gilead Sciences, Inc.
• Celgene Corporation
• AstraZeneca PLC
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

The competitive landscape of the oncology injection drug sales market is characterized by the presence of numerous pharmaceutical companies, each striving to innovate and capture market share in a rapidly evolving environment. Major players such as Roche Holding AG and Merck & Co., Inc. lead the market with a robust portfolio of oncology therapies that include monoclonal antibodies, targeted therapies, and immunotherapies. These companies invest heavily in research and development to ensure a steady pipeline of new products while also focusing on strategic partnerships and collaborations to enhance their market position. The competition is further intensified by the emergence of biosimilars and generic drugs that challenge the dominance of established branded products.

Companies such as Bristol-Myers Squibb and Johnson & Johnson are also significant players, with a strong commitment to advancing cancer treatment through innovative therapies. Their portfolios include a range of effective oncology drugs that target various cancer types. These companies leverage their extensive clinical trial networks to accelerate the development and approval of new therapies, positioning themselves as leaders in the oncology space. Additionally, the increasing trend toward combination therapies has prompted these companies to explore partnerships with other firms to develop synergistic treatment options that improve patient outcomes.

Furthermore, emerging players and biotechnology firms are entering the oncology injection drug market, bringing new and innovative therapies to the forefront. Companies like Gilead Sciences and Celgene Corporation are making strides in developing novel cancer treatments that address unmet needs in the market. The focus on personalized medicine and targeted therapies is driving these companies to prioritize research and development efforts, ensuring they remain competitive in this dynamic landscape. Overall, the oncology injection drug sales market is characterized by intense competition, with established players and newcomers alike striving to deliver effective and innovative therapies to meet the growing demand for cancer treatment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca PLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Celgene Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Oncology Injection Drug Sales Market, By Application
    • 6.1.1 Solid Tumors
    • 6.1.2 Hematologic Malignancies
  • 6.2 Oncology Injection Drug Sales Market, By Product Type
    • 6.2.1 Monoclonal Antibodies
    • 6.2.2 Chemotherapy Drugs
    • 6.2.3 Targeted Therapy Drugs
    • 6.2.4 Immunotherapy Drugs
    • 6.2.5 Hormone Therapy Drugs
  • 6.3 Oncology Injection Drug Sales Market, By Ingredient Type
    • 6.3.1 Pembrolizumab
    • 6.3.2 Rituximab
    • 6.3.3 Trastuzumab
    • 6.3.4 Bevacizumab
    • 6.3.5 Ipilimumab
  • 6.4 Oncology Injection Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Oncology Injection Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Oncology Injection Drug Sales market is categorized based on

By Product Type

• Monoclonal Antibodies
• Chemotherapy Drugs
• Targeted Therapy Drugs
• Immunotherapy Drugs
• Hormone Therapy Drugs

By Application

• Solid Tumors
• Hematologic Malignancies

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies

By Ingredient Type

• Pembrolizumab
• Rituximab
• Trastuzumab
• Bevacizumab
• Ipilimumab

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Merck & Co., Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Gilead Sciences, Inc.
• Celgene Corporation
• AstraZeneca PLC
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.